Valuation: Biodesix, Inc.

Market Cap 243M 211M 197M 180M 339M 23.16B 345M 2.31B 905M 11.61B 914M 894M 38.38B P/E 2026 *
-8.89x
P/E 2027 * -13.9x
Enterprise Value 243M 211M 197M 180M 339M 23.16B 345M 2.31B 905M 11.61B 914M 894M 38.38B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 1.81x
Free-Float
54.63%
Yield 2026 *
-
Yield 2027 * -
1 day+6.33%
1 week+10.85%
Current month+10.85%
1 month+16.63%
3 months+53.39%
6 months+126.40%
Current year+245.59%
1 week 19.77
Extreme 19.77
25
1 month 19.09
Extreme 19.09
25
Current year 5.26
Extreme 5.26
25
1 year 5.26
Extreme 5.26
25
3 years 3.44
Extreme 3.436
44.2
5 years 3.44
Extreme 3.436
204.4
10 years 3.44
Extreme 3.436
639.8
Manager TitleAgeSince
Chief Executive Officer 54 2019-12-31
Director of Finance/CFO 46 2017-03-31
Chief Tech/Sci/R&D Officer - 2015-12-31
Director TitleAgeSince
Chairman 79 2020-09-13
Director/Board Member 53 2011-12-31
Director/Board Member 59 2020-03-31
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Fiscal year

Chairman

2,722 0.0340%
2/20/26 Fiscal year

Executive/Senior Manager

3,612 0.0452%
2/20/26 Fiscal year

Controller/Auditor

1,337 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
+6.33%+10.85%+193.38%-26.56% 243M
+21.37%+20.29%+111.98%+510.96% 46.43B
+0.83%+3.22%+20.06%+49.24% 25.88B
+0.04%+1.78%-19.56%-35.04% 7.76B
+6.20%+13.49%+35.65%+128.20% 5.69B
+0.19%+1.39%+21.09%+63.03% 3.39B
+10.76%+18.38%-26.68%+1,059.10% 2.3B
+6.49%+8.37%+185.69%+8.16% 2.13B
+11.67%+10.56%+32.06%+23.05% 2.02B
+3.35%+4.36%-4.07%-55.62% 1.99B
Average +6.72%+8.89%+54.96%+172.45% 9.78B
Weighted average by Cap. +11.45%+12.14%+64.17%+286.69%

Financials

2026 *2027 *
Net sales 112M 96.72M 90.33M 82.86M 156M 10.64B 158M 1.06B 416M 5.33B 420M 411M 17.63B 135M 116M 109M 99.72M 188M 12.81B 191M 1.28B 501M 6.42B 505M 494M 21.22B
Net income -26.99M -23.35M -21.8M -20M -37.62M -2.57B -38.22M -256M -100M -1.29B -101M -99.14M -4.26B -18.13M -15.68M -14.64M -13.43M -25.27M -1.73B -25.67M -172M -67.43M -865M -68.07M -66.58M -2.86B
Net Debt - -
Logo Biodesix, Inc.
Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.
Employees
334
Date Price Change Volume
26-08-07 US$23.50 +6.33% 81,127
26-08-06 US$22.10 -2.99% 233,019
26-08-05 US$22.78 +0.11% 43,090
26-08-04 US$22.76 +3.29% 57,277
26-08-03 US$22.03 +3.92% 86,244
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
23.50USD
Average target price
32.67USD
Spread / Average Target
+39.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDSX Stock